Taeuber I, Weibel S, Herrmann E, et al. - Researchers investigated how intravenous tranexamic acid (TXA; an efficient antifibrinolytic agent) is associated with total thromboembolic events (TEs) and mortality in patients of all ages and of any medical disciplines. They conducted a systematic review and meta-analysis including 216 studies of 125,550 patients undergoing surgical procedures and receiving either intravenous administration of tranexamic acid or placebo or no treatment. Findings revealed 1,020 (2.1%) thromboembolic events in the tranexamic acid group and 900 (2.0%) total thromboembolic events in the control group. No increased risk of any thromboembolic event was observed in patients of all medical disciplines. Intravenous TXA, irrespective of dosing, is herein suggested to have no correlation with raised risk of any TE.